{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(1)"],"submitter":["Piper-Vallillo AJ"],"funding":["Stand Up To Cancer","LUNGevity Foundation","Mark Foundation For Cancer Research"],"pubmed_abstract":["<h4>Introduction</h4>Lung cancer is associated with severe coronavirus disease 2019 (COVID-19) infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incidence, symptoms, differential diagnosis, and outcomes of COVID-19 in patients with lung cancer.<h4>Methods</h4>To determine an at-risk population for COVID-19, we retrospectively identified patients with lung cancer receiving longitudinal care within a single institution in the 12 months (April 1, 2019 to March 31, 2020) immediately preceding the COVID-19 pandemic, including an \"active therapy population\" treated within the last 60 days of this period. Among patients subsequently referred for COVID-19 testing, we compared symptoms, laboratory values, radiographic findings, and outcomes of positive versus negative patients.<h4>Results</h4>Between April 1, 2019 and March 31, 2020, a total of 696 patients received longitudinal care, including 406 (58%) in the active therapy population. Among 55 patients referred for COVID-19 testing, 24 (44%) were positive for COVID-19, representing a cumulative incidence of 3.4% (longitudinal population) and 1.5% (active therapy population). Compared with patients who were COVID-19 negative, those who were COVID-19 positive were more likely to have a supplemental oxygen requirement (11% versus 54%, <i>p</i> = 0.005) and to have typical COVID-19 pneumonia imaging findings (5 versus 56%, <i>p</i> = 0.001). Otherwise, there were no marked differences in presenting symptoms. Among patients who were COVID-19 negative, alternative etiologies included treatment-related toxicity (26%), atypical pneumonia (22%), and disease progression (22%). A total of 16 patients positive for COVID-19 (67%) required hospitalization, and seven (29%) died from COVID-related complications.<h4>Conclusions</h4>COVID-19 was infrequent in this lung cancer population, but these patients experienced high rates of morbidity and mortality. Oncologists should maintain a low threshold for COVID-19 testing in patients with lung cancer presenting with acute symptoms."],"journal":["JTO clinical and research reports"],"pagination":["100124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7659804"],"repository":["biostudies-literature"],"pubmed_title":["Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations."],"pmcid":["PMC7659804"],"pubmed_authors":["Reynolds KL","Stevens S","Farago A","Mooradian MJ","Piper-Vallillo AJ","Yeap BY","Willers H","Sequist LV","Sakhi M","Heist RS","Gavralidis A","Goodwin K","Gainor JF","Meador CB","Zubiri L","Miller A","Temel JS","Dagogo-Jack I","Digumarthy S","Lin JJ","Vaughn J","Lennes IT","Do A","Peterson J","Piotrowska Z"],"additional_accession":[]},"is_claimable":false,"name":"Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations.","description":"<h4>Introduction</h4>Lung cancer is associated with severe coronavirus disease 2019 (COVID-19) infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incidence, symptoms, differential diagnosis, and outcomes of COVID-19 in patients with lung cancer.<h4>Methods</h4>To determine an at-risk population for COVID-19, we retrospectively identified patients with lung cancer receiving longitudinal care within a single institution in the 12 months (April 1, 2019 to March 31, 2020) immediately preceding the COVID-19 pandemic, including an \"active therapy population\" treated within the last 60 days of this period. Among patients subsequently referred for COVID-19 testing, we compared symptoms, laboratory values, radiographic findings, and outcomes of positive versus negative patients.<h4>Results</h4>Between April 1, 2019 and March 31, 2020, a total of 696 patients received longitudinal care, including 406 (58%) in the active therapy population. Among 55 patients referred for COVID-19 testing, 24 (44%) were positive for COVID-19, representing a cumulative incidence of 3.4% (longitudinal population) and 1.5% (active therapy population). Compared with patients who were COVID-19 negative, those who were COVID-19 positive were more likely to have a supplemental oxygen requirement (11% versus 54%, <i>p</i> = 0.005) and to have typical COVID-19 pneumonia imaging findings (5 versus 56%, <i>p</i> = 0.001). Otherwise, there were no marked differences in presenting symptoms. Among patients who were COVID-19 negative, alternative etiologies included treatment-related toxicity (26%), atypical pneumonia (22%), and disease progression (22%). A total of 16 patients positive for COVID-19 (67%) required hospitalization, and seven (29%) died from COVID-related complications.<h4>Conclusions</h4>COVID-19 was infrequent in this lung cancer population, but these patients experienced high rates of morbidity and mortality. Oncologists should maintain a low threshold for COVID-19 testing in patients with lung cancer presenting with acute symptoms.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2024-11-06T06:37:22.177Z","creation":"2021-02-21T00:40:50Z"},"accession":"S-EPMC7659804","cross_references":{"pubmed":["33205053"],"doi":["10.1016/j.jtocrr.2020.100124"]}}